Probiotics and Covid-19

Bottari, Benedetta; Castellone, Vincenzo; Neviani, Erasmo

doi:10.1080/09637486.2020.1807475

Cited by 90 publications

(70 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the period between the emergence of a new mutant virus and the development and testing of an effective vaccine, safe and low-cost prophylactic agents with nonspecific immune, anti-inflammatory, and antiviral effects could provide an avenue for intervention. Probiotics and prebiotics have been suggested as candidate components of preventative and acute care strategies for COVID-19 infection [92][93][94]. Known for their ability to regulate multiple aspects of the immune response [95], a body of evidence has previously demonstrated the effectiveness of specific probiotics in preventing upper respiratory tract viral infections [96] and reducing the risk of ventilator-associated pneumonia [92].…”

Section: Open Accessmentioning

confidence: 99%

Shaping the Future of Probiotics and Prebiotics

Cunningham¹,

Azcárate-Peril

Barnard³

et al. 2021

Trends in Microbiology

349

203

View full text Add to dashboard Cite

Recent and ongoing developments in microbiome science are enabling new frontiers of research for probiotics and prebiotics. Novel types, mechanisms, and applications currently under study have the potential to change scientific understanding as well as nutritional and healthcare applications of these interventions. The expansion of related fields of microbiome-targeted interventions, and an evolving landscape for implementation across regulatory, policy, prescriber, and consumer spheres, portends an era of significant change. In this review we examine recent, emerging, and anticipated trends in probiotic and prebiotic science, and create a vision for broad areas of developing influence in the field. HighlightsAn expanding range of candidate probiotic species and prebiotic substrates is emerging to address newly elucidated data-driven microbial niches and host targets.Overlapping with, and adjacent to, the probiotic and prebiotic fields, new variants of microbiome-modulating interventions are developing, including synbiotics, postbiotics, microbial consortia, live biotherapeutic products, and genetically modified organisms, with renewed interest in polyphenols, fibres, and fermented foods.

show abstract

Section: Open Accessmentioning

confidence: 99%

Shaping the Future of Probiotics and Prebiotics

Cunningham¹,

Azcárate-Peril

Barnard³

et al. 2021

Trends in Microbiology

349

203

View full text Add to dashboard Cite

show abstract

“…While many probiotics have evidence-based efficacy for the prevention of AAD and CDI, few studies have been published in COVID-19 patients. The use of probiotics in COVID-19 patients has been suggested by many investigators, based on the ability of specific probiotics to regulate the immune response (perhaps to calm the “cytokine storm”), or to prevent other types of respiratory infections, including influenza and ventilator-associated pneumonia and to prevent AAD and CDI [ 50 , 51 , 52 ]. We thus propose that some probiotics with efficacy for AAD and CDI might be potential therapies in COVID-19 patients, preventing the consequences of the heavy use of antibiotics in these patients.…”

Section: Potential Use Of Probiotics For Antibiotic-associated Complicationsmentioning

confidence: 99%

Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use

Kullar¹,

Johnson

McFarland

et al. 2021

Antibiotics

View full text Add to dashboard Cite

Medical care for patients hospitalized with COVID-19 is an evolving process. Most COVID-19 inpatients (58–95%) received empiric antibiotics to prevent the increased mortality due to ventilator-associated pneumonia and other secondary infections observed in COVID-19 patients. The expected consequences of increased antibiotic use include antibiotic-associated diarrhea (AAD) and Clostridioides difficile infections (CDI). We reviewed the literature (January 2020–March 2021) to explore strategies to reduce these consequences. Antimicrobial stewardship programs were effective in controlling antibiotic use during past influenza epidemics and have also been shown to reduce healthcare-associated rates of CDI. Another potential strategy is the use of specific strains of probiotics shown to be effective for the prevention of AAD and CDI prior to the pandemic. During 2020, there was a paucity of published trials using these two strategies in COVID-19 patients, but trials are currently ongoing. A multi-strain probiotic mixture was found to be effective in reducing COVID-19-associated diarrhea in one trial. These strategies are promising but need further evidence from trials in COVID-19 patients.

show abstract

“…Furthermore, some reports have shown the presence of RNA of SARS-CoV-2 in fecal samples of some infected patients that tested negative for the presence of SARS-CoV-2 RNA in their respiratory samples (Wu et al 2020;Xiao et al 2020;Kopel et al 2020). These shreds of evidence suggest crosstalk between the gut-lung axis, which to some extent may be modulated by probiotics, by favorably altering the gastrointestinal symptoms and shielding the respiratory system (Gu et al 2020;Bottari et al 2020). Therefore, this review article emphasizes to provide insights into the possible role of probiotics in COVID-19 prevention, in so doing, providing a starting point for future studies on it.…”

Section: Introductionmentioning

confidence: 99%

Probiotics in the prophylaxis of COVID-19: something is better than nothing

et al. 2020

View full text Add to dashboard Cite

The new viral pandemic of COVID-19 is caused by a novel coronavirus (SARS-CoV-2) that has brought the world at another unprecedented crisis in terms of health and economy. The lack of specific therapeutics necessitates other strategies to prevent the spread of infection caused by this previously unknown viral etiological agent. Recent pieces of evidence have shown an association between COVID-19 disease and intestinal dysbiosis. Probiotics comprise living microbes that upon oral administration benefit human health by reshaping the composition of gut microbiota. The close kinship of the gastrointestinal and respiratory tract suggests why the dysfunction of one may incite illness in others. The emerging studies suggest the capability of probiotics to regulate immune responses in the respiratory system. The efficacy of probiotics has been studied previously on several respiratory tract viral infections. Therefore, the purpose of this review is to comprehend existing information on the gut mediated-pulmonary immunity conferred by probiotic bacteria, in the course of respiratory virus infections and administration as a prophylactic measure in COVID-19 pandemic in managing intestinal dysbiosis as well.

show abstract

Probiotics and Covid-19

Cited by 90 publications

References 53 publications

Shaping the Future of Probiotics and Prebiotics

Shaping the Future of Probiotics and Prebiotics

Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use

Probiotics in the prophylaxis of COVID-19: something is better than nothing

Contact Info

Product

Resources

About